Shanghai, China – Shanghai MicroPort Medical (Group) Co ("MicroPort®") recently attended AsiaPCR 2016 held in Singapore. During the premier cardiovascular course that attracted over 2,000 cardiovascular professionals from 12 Asian countries including China, India, Malaysia, Japan and South Korea, MicroPort® displayed the excellent performance of its innovative stents and demonstrated its growth potentials, enabling more patients to know about and benefit from MicroPort® products.
On the first day of the conference, MicroPort® live broadcasted a PCI operation in which Firebird2® Rapamycin-Eluting Coronary CoCr Stent System ("Firebird2®") was used to cure left main bifurcation lesions. Conducted by Professor Shaoliang Chen and his team from Nanjing First Hospital, the operation showed that Firebird2® was successfully implanted into the occlusive coronary artery of a patient with severe coronary heart diseases. The excellent crossability of Firebird2® was spoken highly by Professor Chen as well as Asia PCR attendees.
Meanwhile, MicroPort® exhibited its cardiovascular devices and surgical management products in its booth, which attracted many interests and stimulated discussions of future business cooperation. Professor Runlin Gao of Fuwai Hospital visited MicroPort® booth and gave high praise to the prominent features of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"), such as its outstanding crossability and low drug dosage. Vice President of MicroPort® International Business Linda Lin also took this opportunity to call on Professor KOH Tian-Hai from National Heart Centre Singapore, introducing to him Firehawk®'s design concepts and clinical researches, and exchanging opinions on Firehawk®'s market development prospect in Singapore.